Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study

[1]  A. Giustina,et al.  Effects of octreotide on autophagy markers and cell viability markers related to metabolic activity in rat pituitary tumor cells , 2020, Pituitary.

[2]  P. Chanson,et al.  Acromegaly , 2019, Nature Reviews Disease Primers.

[3]  P. Chanson,et al.  Signs and symptoms of acromegaly at diagnosis: the physician’s and the patient’s perspectives in the ACRO-POLIS study , 2018, Endocrine.

[4]  P. Chanson,et al.  A Consensus Statement on acromegaly therapeutic outcomes , 2018, Nature Reviews Endocrinology.

[5]  Fahad M. Alshahrani,et al.  Management of acromegaly: an exploratory survey of physicians from the Middle East and North Africa , 2018, Hormones.

[6]  X. Badia,et al.  Development of ACRODAT®, a new software medical device to assess disease activity in patients with acromegaly , 2017, Pituitary.

[7]  P. Chanson,et al.  Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement , 2017, Pituitary.

[8]  P. Chanson,et al.  SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study , 2015, Pituitary.

[9]  J. Honegger,et al.  Failure to achieve disease control in acromegaly: cause analysis by a registry-based survey. , 2015, European journal of endocrinology.

[10]  A. Mamelak,et al.  A structural and functional acromegaly classification. , 2015, The Journal of clinical endocrinology and metabolism.

[11]  E. Laws,et al.  Acromegaly: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[12]  P. Chanson,et al.  A consensus on the diagnosis and treatment of acromegaly complications , 2012, Pituitary.

[13]  F. Cordido,et al.  Clinical Manifestations and Diagnosis of Acromegaly , 2012, International journal of endocrinology.

[14]  P. Chanson,et al.  Current management practices for acromegaly: an international survey , 2011, Pituitary.

[15]  P. Chanson,et al.  A consensus on criteria for cure of acromegaly. , 2010, The Journal of clinical endocrinology and metabolism.

[16]  A. Pontecorvi,et al.  Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. , 2009, The Journal of clinical endocrinology and metabolism.

[17]  S. Melmed,et al.  The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. , 2009, The Journal of clinical endocrinology and metabolism.

[18]  B. Velkeniers,et al.  Divergence between growth hormone and insulin-like growth factor-i concentrations in the follow-up of acromegaly. , 2008, The Journal of clinical endocrinology and metabolism.

[19]  X. Badia,et al.  Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. , 2006, European journal of endocrinology.

[20]  X. Badia,et al.  Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. , 2005, The Journal of clinical endocrinology and metabolism.

[21]  F. Casanueva,et al.  Criteria for cure of acromegaly: a consensus statement. , 2000, The Journal of clinical endocrinology and metabolism.